Hemab Therapeutics Reports $24.2 Million Net Loss and $457.5 Million in Cash as of June 30, 2026

Hemab Therapeutics Holdings, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded a net loss of $24.2 million for the quarter, compared to a loss of $12.2 million in the same period last year, reflecting an increase in operating expenses driven primarily by research and development costs. Total operating expenses for the quarter reached $26.1 million, up from $16.1 million in the prior year, with research and development expenses alone rising to $20.3 million from $12.9 million. The increase in expenses is attributed to heightened external research and development costs associated with the company's lead product candidates, sutacimig and HMB-002.

In terms of liquidity, Hemab reported cash, cash equivalents, and marketable securities totaling $457.5 million as of June 30, 2026, a substantial increase from $192.6 million at the end of 2025. This increase is largely due to the company's initial public offering (IPO) completed on May 4, 2026, which generated approximately $317.2 million in net proceeds. The IPO allowed the company to convert all outstanding preferred stock into common stock, simplifying its capital structure. As of June 30, 2026, the company had an accumulated deficit of $228.7 million, reflecting its ongoing investment in product development without generating revenue from product sales.

Operationally, Hemab is advancing its clinical programs, with sutacimig currently in Phase 1/2 trials for Glanzmann thrombasthenia and Factor VII deficiency, and HMB-002 in Phase 1/2 trials for Von Willebrand Disease. The company plans to initiate a Phase 3 clinical trial for sutacimig in the second half of 2026, following positive results from ongoing studies. Additionally, Hemab is developing HMB-003, which is in preclinical stages targeting heavy menstrual bleeding. The company anticipates that these clinical developments will require substantial additional funding, and it is exploring various financing options to support its growth strategy.

The filing also highlighted a corporate reorganization completed in March 2026, which transitioned the company to a Delaware corporation and streamlined its share structure. Despite the positive developments, Hemab acknowledged material weaknesses in its internal controls over financial reporting, which it is actively working to remediate. The company emphasized the need for ongoing investment in its operational infrastructure to support its clinical development and commercialization efforts.

Looking ahead, Hemab expects to continue incurring significant operating losses as it advances its product candidates through clinical trials and seeks regulatory approvals. The company remains focused on its mission to develop innovative therapies for blood coagulation disorders, with a commitment to addressing the unmet needs of patients worldwide.